




Multiparametric imaging in oncology





- The goal of **traditional imaging** is **high spatial and contrast resolution** → diagnosis, tumor extent → treatment planning, surgery.
- When a **non-surgical treatment** is planned, other questions raise: **will it work? Which is the best treatment option?**
- Traditional imaging is not able to provide adequate answers. **Multiparametric imaging** constitutes an attempt to respond these questions, especially.



Multimodal vs multiparametric







- 1) **Multimodal**: combine different **imaging techniques** to work out uncertain findings



From screening to tumor diagnosis; recurrence identification

- 2) **Multiparametric**: combine **information about tumor** to understand more about it.
 - a) quantitative
 - b) the same information can be provided by different imaging techniques (i.e. blood flow \leftarrow pCT, pMR, CEUS, PET).



- Different but not exclusive concepts
- Prostate imaging is an example of intersection: multiparametric imaging to T2W imaging (central and transitional zone cancer)




Cultural switch:



from image interpretation
to **parameter interpretation**;
develop multidimensional and
more abstract thinking



Prediction/early
assessment of
response to treatment




morphology

parameters

function

Why function?

- angiogenesis, hypoxia → biologic characteristics → aggressiveness → prediction of disease control and/or → target-therapy;
- → **towards individual-targeted therapy**






morphology

parameters

function



- Functional changes during treatment predict earlier than morphological changes the response to treatment.





morphology

parameters

function



- Volume is not an indicator of response to treatment for cytostatic drugs (antiangiogenesis, metastatic renal cell cancer, GIST etc.) and other treatments (i.e. TACE) → inadequacy of RECIST criteria.



MRI

- Dynamic contrast enhanced (DCE MRI): **angiogenesis**. Tumor perfusion, vascular permeability, extracellular space. Limitations: reproducibility.
- Dynamic susceptibility contrast (DSC MRI): **perfusion**. Blood flow, blood volume. No information about permeability.
- Diffusion weighted (DWI MR): **cellularity, necrosis**. Limitations: difficult reproducibility, artifacts.



MRI

- Spectroscopy (MRS): **metabolism, proliferation**.
Limitations: low spatial resolution, time demanding, technically challenging.
- Blood oxygenation level dependent (BOLD MRI): **tissue oxygenation**.
Limitations: reflects acute more than chronic hypoxia, time and technically demanding, difficult post-processing.



PET





- FDG PET: **glucose metabolism.**
- Labeled water PET: **perfusion.**
- Fluorothymidine PET: **cellular proliferation.**
- Fluoromisonidazole (MISO) PET: **hypoxia.**
- Iodine annexin V: **apoptosis.**
- Choline PET: **cellular proliferation.**
- Methoxyisobutyl-isonitrile PET: **multidrug resistance.**



First... **Biology**

- The **choice of imaging techniques** is dictated by the functional parameters needed to describe biological characteristics of the tumor or expected effects of specific therapies.
- The **interpretation of imaging results** is guided by the knowledge of tumor's (disregulated) biology.

Normal



- Evading apoptosis
- Self sufficiency in growth signals
- Insensitivity to anti-growth signals
- Limitless replication potential
- Abnormal glucose uptake & metabolism
- Resistance to acid-mediated toxicity
- Tissue invasion and metastasis
- Sustained angiogenesis
- Avoidance of immune surveillance

Altered metabolism & hypoxia

- ¹⁸F-DG-PET
- ¹H and ¹³C MRS
- BOLD-MRI
- ¹⁸F-MISO PET

Angiogenesis

- H₂ ¹⁵O-PET
- DCE-CT
- DCE-MRI
- DCE-US

Apoptosis

- ^{99m}Tc-Annexin V
- Diffusion MRI

Proliferation

- ¹⁸FLT-PET
- ¹H-MRS
- Diffusion MRI

Metastasis

- Lymphography
- Whole body DW-MRI
- Bone scan
- ¹⁸F-DG-PET
- CT etc







The HIF-1 pathway example



- HIF-1 (hypoxia inducible factor) activates a cascade of events that lead to hypoxia adaptation:
 - ? Metabolism: Warburg effect (? GLUT1 and hexokinase → ? glycolysis, lactate production and extrusion, resistance to acid environment).
 - ? Angiogenesis (via VEGF).
 - ? Chemotherapy resistance (p-glycoprotein upregulation)
- HIF-1 can be actually induced by hypoxia (RT resistance) or constitutionally up-regulated (p53 mutation)
- **HIF activation by hypoxia > HIF activation by gene mutation**



Naming and filling the cube





Prediction of treatment response



Hypoxia	Perfusion	Glucose Metabolism	Significance
Absent	Low	Moderate	No constitutive upregulation of angiogenesis or metabolism Query low tumor aggression/low grade neoplasm Query low treatment resistance
Absent	High	High	Probable constitutive upregulation of angiogenesis and metabolism Query moderate tumor aggression Query moderate treatment resistance
Present	Low	Low	Necrosis
Present	Low	Moderate	Failure of adaptation to hypoxia Query tumor aggression Query moderate treatment resistance
Present	Low	High	Adaptation to hypoxia High tumor aggression Likely treatment resistance

- Mismatch between perfusion (low) and metabolism (high) → poor prognosis




Prediction of treatment response



To correlate or not to correlate? – The patient level

Trying to understand the mixed correlations at the **patient level**.

→ Need to match the individual results with the individual biology and/or the response to treatment






Prediction of treatment response



To correlate or not to correlate? – The voxel level and the tumor heterogeneity.

Trying to understand the correlations at the voxel level.

→ Need to match the results with the biological heterogeneity within the tumor and/or the response to treatment.




Scatter width (σ) correlates with outcome (local relapse + or -) in head and neck cancers.







Prediction of treatment response



Advanced breast cancer – PET, 37 patients








Early assessment during therapy

- Adding two variables: treatment effects and time → **complexity increase**
- Numerous studies about single functional techniques. **Very few studies** about multiparametric imaging.



Vascular normalization index (VNI) unifies in a single parameter: ΔK^{trans} , ΔCBV , $\Delta ColI-IV$.

It well predicted FPS and OS in glioblastoma multiforme after a single dose of anti-VEGFR.



Future: when and how



- Multiparametric imaging is already future
- Need of multicentric prospective studies.
- Need of technical standardization (MRI)
- Need of new-concept informatic platforms to analyse, visualize and interpolate functional data.



Thank you

